Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Kobold

Showing results (91-100 of 177) with videos related to

Pageof 18
Sort By:
Journal of the National Cancer Institute|June 25, 2015
Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell TherapySebastian Kobold, Simon Grassmann, Michael Chaloupka, et al.
Journal of the American Society of Nephrology : JASN|January 25, 2014
Toll-like receptor 4-induced IL-22 accelerates kidney regenerationOnkar P Kulkarni, Ingo Hartter, Shrikant R Mulay, et al.
JCI Insight|March 9, 2018
Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gutRachel Mak'Anyengo, Peter Duewell, Cornelia Reichl, et al.
Molecular Cancer Therapeutics|January 2, 2026
Proteolysis targeting chimeric-based technology in myeloma and lymphomaAdrian Bogdan Tigu, Andrei Ivancuta, Ciprian Tomuleasa, et al.
British Journal of Cancer|November 16, 2018
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapyFelicitas Rataj, Severin J Jacobi, Stefan Stoiber, et al.
Clinical & Developmental Immunology|April 7, 2012
Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patientsSebastian Kobold, Tim Luetkens, Britta Marlen Bartels, et al.
Journal for Immunotherapy of Cancer|December 18, 2019
Correction to: Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancerPhilipp Metzger, Sabrina V Kirchleitner, Michael Kluge, et al.
Current Oncology (Toronto, Ont.)|January 20, 2022
The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid TumorsJulian Kolorz, Salih Demir, Adrian Gottschlich, et al.
Journal for Immunotherapy of Cancer|November 8, 2019
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancerPhilipp Metzger, Sabrina V Kirchleitner, Michael Kluge, et al.
Haematologica|December 18, 2009
Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cellsDjordje Atanackovic, York Hildebrandt, Adam Jadczak, et al.
Pageof 18

Showing results (91-100 of 177) with videos related to

Sort By:
Pageof 18
Journal of the National Cancer Institute|June 25, 2015
Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell TherapySebastian Kobold, Simon Grassmann, Michael Chaloupka, et al.
Journal of the American Society of Nephrology : JASN|January 25, 2014
Toll-like receptor 4-induced IL-22 accelerates kidney regenerationOnkar P Kulkarni, Ingo Hartter, Shrikant R Mulay, et al.
JCI Insight|March 9, 2018
Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gutRachel Mak'Anyengo, Peter Duewell, Cornelia Reichl, et al.
Molecular Cancer Therapeutics|January 2, 2026
Proteolysis targeting chimeric-based technology in myeloma and lymphomaAdrian Bogdan Tigu, Andrei Ivancuta, Ciprian Tomuleasa, et al.
British Journal of Cancer|November 16, 2018
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapyFelicitas Rataj, Severin J Jacobi, Stefan Stoiber, et al.
Clinical & Developmental Immunology|April 7, 2012
Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patientsSebastian Kobold, Tim Luetkens, Britta Marlen Bartels, et al.
Journal for Immunotherapy of Cancer|December 18, 2019
Correction to: Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancerPhilipp Metzger, Sabrina V Kirchleitner, Michael Kluge, et al.
Current Oncology (Toronto, Ont.)|January 20, 2022
The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid TumorsJulian Kolorz, Salih Demir, Adrian Gottschlich, et al.
Journal for Immunotherapy of Cancer|November 8, 2019
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancerPhilipp Metzger, Sabrina V Kirchleitner, Michael Kluge, et al.
Haematologica|December 18, 2009
Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cellsDjordje Atanackovic, York Hildebrandt, Adam Jadczak, et al.
Pageof 18